Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 2 4Phase 1/2 3Phase EARLY_PHASE1 1

Status

Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Melanoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Carcinoma, Transitional Cell 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Interventional × urelumab × Clear all
NCT02845323 2026-04-06

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
15 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02451982 2025-12-03

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
76 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02420938 2016-12-06

Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

M.D. Anderson Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00612664 2015-10-12

Phase II, 2nd Line Melanoma - RAND Monotherapy

Bristol-Myers Squibb

Phase 2 Completed
158 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡